首页> 美国卫生研究院文献>other >Agreement Between the European Organization for Research and Treatment of Cancer and Positron Emission Tomography Response Criteria in Solid Tumors in Evaluating Treatment Response in Solid Malignant Tumors
【2h】

Agreement Between the European Organization for Research and Treatment of Cancer and Positron Emission Tomography Response Criteria in Solid Tumors in Evaluating Treatment Response in Solid Malignant Tumors

机译:欧洲癌症研究和治疗组织与实体瘤中的正电子发射断层扫描响应标准之间的协议用于评估实体恶性肿瘤的治疗响应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

IntroductionFluorine-18 fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) is used for non-invasive staging and restaging of solid malignant tumors. PET-CT based criteria have been developed to evaluate the response to targeted therapy. These include the European Organization for Research and Treatment of Cancer (EORTC) and the PET Response Criteria in Solid Tumors (PERCIST). The aim of this study was to determine the agreement between EORTC and PERCIST criteria for treatment response evaluation in patients with solid malignant tumors.Materials and methodsThis was a retrospective study conducted from February 2017 till July 2017. Electronic medical records of patients diagnosed with solid malignant tumors were searched. Experienced radiologists evaluated the PET-CT images based on EORTC and PERCIST criteria. The Kappa (κ) test was used for evaluation of agreement between treatment response according to EORTC and PERCIST criteria.ResultsOut of 54 patients, 41 (75.9%) were male and 13 (24.1%) were female with a mean age of 57.09 ± 10.65 years. According to EORTC criteria, complete metabolic response (CMR) was seen in five (9.3%) of patients, partial metabolic response (PMR) was seen in 36 (66.7%) of patients, progressive metabolic disease (PMD) was seen in nine (16.7%) of patients and stable metabolic disease (SMD) was seen in four (7.4%) of patients. According to PERCIST criteria, CMR was seen in five (9.3%) of patients, PMR was seen in 33 (61.1%) of patients, PMD was seen in nine (16.7%) of patients and SMD was seen in seven (13.0%) of patients. EORTC and PERCIST agreed on 43 (79.6%) of the patients with κ-coefficient of 0.62 indicating good agreement (p-value of <0.001).ConclusionEORTC and PERCIST criteria have a good agreement in evaluating treatment response in solid malignant tumors. Therefore, adoption of EORTC or PERCIST in PET-CT reporting can standardize the evaluation of oncological treatment results.
机译:简介氟18氟脱氧葡萄糖(FDG)正电子发射断层扫描计算机断层扫描(PET-CT)用于无创分期和重分类实体恶性肿瘤。已经开发了基于PET-CT的标准来评估对靶向治疗的反应。其中包括欧洲癌症研究和治疗组织(EORTC)和实体瘤PET反应标准(PERCIST)。这项研究的目的是确定EORTC和PERCIST标准之间对实体恶性肿瘤患者的治疗反应评估的一致性。材料和方法这是一项回顾性研究,于2017年2月至2017年7月进行。诊断为实体恶性肿瘤的患者的电子病历搜索了肿瘤。经验丰富的放射科医生根据EORTC和PERCIST标准评估了PET-CT图像。根据EORTC和PERCIST标准,使用Kappa(κ)检验评估治疗反应之间的一致性。结果54例患者中,男性41例(75.9%),女性13例(24.1%),平均年龄为57.09±10.65年份。根据EORTC标准,五名患者(9.3%)出现了完全代谢反应(CMR),三十六名患者(66.7%)出现了部分代谢反应(PMR),九名患者出现了进行性代谢疾病(PMD)(患者中有16.7%的患者患有稳定代谢病(SMD),其中有四名(7.4%)患者。根据PERCIST标准,五位患者(9.3%)发生CMR,33位患者(61.1%)发生PMR,九位患者(16.7%)发生PMD,七位患者(13.0%)发生SMD。的患者。 EORTC和PERCIST同意43例患者(79.6%)的κ系数为0.62,表明一致性良好(p值<0.001)。结论E​​ORTC和PERCIST标准在评估实体恶性肿瘤的治疗反应方面具有良好的一致性。因此,在PET-CT报告中采用EORTC或PERCIST可以标准化对肿瘤治疗结果的评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号